Associated Genetic Biomarkers

Overview

Cancers most frequently harbor alterations in TP53, KRAS, PIK3CA, APC, and CDKN2A [2].

Most Commonly Altered Genes in Cancer

TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in cancer [2].

Top Alterations in Cancer

Significant Genes in Cancer

ABL1 +

AKT1 +

AKT2 +

AKT3 +

ALK +

ARID1A +

ATM +

ATR +

AXL +

BRAF +

BRCA1 +

BRCA2 +

C11ORF30 +

CCND1 +

CCND3 +

CDK4 +

CDK6 +

CDKN2A +

CRKL +

EGFR +

ERBB2 +

FANCA +

FANCB +

FANCC +

FANCD2 +

FANCE +

FANCF +

FANCG +

FANCI +

FANCL +

FANCM +

FGF1 +

FGF10 +

FGF11 +

FGF12 +

FGF13 +

FGF14 +

FGF16 +

FGF17 +

FGF18 +

FGF19 +

FGF2 +

FGF20 +

FGF21 +

FGF22 +

FGF23 +

FGF3 +

FGF4 +

FGF5 +

FGF6 +

FGF7 +

FGF8 +

FGF9 +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

FLT1 +

FLT3 +

FLT4 +

HRAS +

IDH1 +

IGH +

IRS2 +

KDR +

KIT +

KRAS +

MAGEA3 +

MAP2K1 +

MET +

MLH1 +

MLH3 +

MRE11A +

MSH2 +

MSH3 +

MSH6 +

MTOR +

NBN +

NF1 +

NF2 +

NRAS +

PALB2 +

PDGFRA +

PDGFRB +

PIK3CA +

PIK3CG +

PIK3R1 +

PIK3R2 +

PMS1 +

PMS2 +

PTEN +

RAD50 +

RET +

RHEB +

RICTOR +

RNF43 +

ROS1 +

RPTOR +

STK11 +

TP53 +

TSC1 +

TSC2 +

Disease Details

Children
Cancer, NOS, Metastatic Malignant Neoplasm in the Brain, Histiocytic And Dendritic Cell Cancer, Plasmacytoma, Immunodeficiency-Related Malignant Neoplasm, Secondary Malignant Neoplasm, Therapy-Related Malignant Neoplasm, Cell Type Cancer, Hematopoietic and Lymphoid Malignancy, Undifferentiated Malignant Neoplasm, Malignant Solid Tumor, and Plasma Cell Neoplasm

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.